Published regulatory strategy

Lumvoa (veligrotug-vvze) Public Development Program - Lumvoa (veligrotug-vvze; VRDN-001/ZB001) - Treatment of thyroid eye disease regardless of thyroid eye disease activity or duration

Lumvoa (veligrotug-vvze; VRDN-001/ZB001) · Treatment of thyroid eye disease regardless of thyroid eye disease activity or duration

Published snapshot · read only · drag elements vertically to inspect the layout

Claims and evidence 6

Intended claim

Two-study registrational architecture supports broad TED indicationTwo adequate and well-controlled Phase 3 trials support efficacy across active and chronic TED.Independent positive pivotal trials in the two disease-duration populations supporting the intended broad label. · Supports the indication regardless of TED activity or duration.
10 mg/kg Q3W for five infusions is an adequate registration regimen10 mg/kg IV every three weeks for five infusions.Dose-ranging support, pivotal efficacy, and FDA agreement on the five-infusion pivotal design. · Defines the approved dosing regimen.

Evidence gaps

Pivotal efficacy resultsDurability after treatment is less complete than Week 15 response, particularly in chronic TED.Strong · FDA Risk Review and Statistical Review
Trial conduct and statistical data quality supported interpretabilityInspection conclusions apply to the inspected sites and submitted datasets.Strong · FDA Clinical Inspection Summary and Statistical Review
To-be-marketed formulation used in pivotal trialsNone identified by the clinical pharmacology review.Strong · FDA Clinical Pharmacology Review
Nonclinical package supported clinical and marketing reviewNo rodent pharmacologic activity; FDA granted carcinogenicity and embryofetal toxicity study waivers.Strong · FDA Pharmacology/Toxicology Review

Studies and FDA questions 19

Studies and endpoints

VRDN-001-101 Phase 1/2 MADRandomized, double-masked, placebo-controlled multiple-ascending-dose portion evaluating safety, tolerability, preliminary efficacy, PK and PD across 3, 10 and 20 mg/kg. Two IV infusions were given three weeks apart.Phase 1/2 · Completed
ZB001-01-001 SADPhase 1 open-label single-ascending-dose study in healthy Chinese subjects evaluating safety, tolerance and PK at 3, 10 and 20 mg/kg IV.Phase 1 · Completed
THRIVE (VRDN-001-101 Phase 3)Pivotal Phase 3 multicenter, prospective, randomized 2:1, double-masked, placebo-controlled trial in moderate-to-severe active TED. Participants received 10 mg/kg veligrotug or placebo every three weeks for five infusions, with primary assessment at Week 15 and follow-up through Week 52.Phase 3 · Completed
ZB001-01-002 MADPhase 1 open-label multiple-ascending-dose study in Chinese participants with active TED. Four IV doses at 3 or 10 mg/kg were administered three weeks apart, assessing safety, tolerability, efficacy, PK, PD and immunogenicity.Phase 1 · Completed
VRDN-001-102 bioavailabilityPhase 1 randomized open-label study in healthy volunteers comparing a single 300 mg subcutaneous injection with a single 3.5 mg/kg intravenous infusion.Phase 1 · Completed
THRIVE-2 (VRDN-001-301)Pivotal Phase 3 randomized 2:1, double-masked, placebo-controlled trial in moderate-to-severe chronic TED. Participants received five 10 mg/kg IV infusions or placebo every three weeks, with primary assessment at Week 15 and follow-up through Week 52.Phase 3 · Completed
VRDN-001-103 multiple-dose safetyPhase 1 randomized, double-masked, placebo-controlled healthy-volunteer study evaluating safety and tolerability of the intended five-infusion 10 mg/kg regimen.Phase 1 · Completed
VRDN-001-302 open-label extensionPhase 3 open-label extension providing veligrotug 10 mg/kg every three weeks for five infusions to participants who were nonresponders at the end-of-treatment assessment in THRIVE or THRIVE-2.Phase 3 · Completed
STRIVE (VRDN-001-303)Phase 3 randomized 3:1, controlled, double-masked safety study comparing the to-be-marketed 10 mg/kg regimen with a 3 mg/kg active-control dose in participants with TED of any duration or activity.Phase 3 · Completed

FDA meetings

Type B pre-IND meetingFDA agreed with the proposed design for the Phase 1/2 VRDN-001-101 study, including the proposed primary efficacy endpoint based on the submitted synopsis.TYPE_B · Meeting scope is captured in this strategy.
Type C development meetingFDA discussed clinical, nonclinical, and CMC development. FDA conveyed safety database expectations and agreed to the pivotal populations and primary endpoint approach if multiplicity was addressed.TYPE_C · Meeting scope is captured in this strategy.
Type B End-of-Phase 2 meetingFDA did not object to evaluating 10 mg/kg in Phase 3, but stated it was premature to call 10 mg/kg the most safe and efficacious dose and encouraged further dose-ranging.TYPE_B_EOP · 1 FDA question
Type C pivotal-design meetingFDA agreed the 8-infusion arm could be eliminated from VRDN-001-101, accepted the Week 15 proptosis responder endpoint for the pivotal program, agreed TED of any duration could be included in STRIVE, and agreed with a controlled masked 10 mg/kg versus very-low-dose design. FDA reiterated safety-database expectations and requested durability assessment at least 24 weeks after the last infusion.TYPE_C · Meeting scope is captured in this strategy.
Type D CMC meetingA Type D CMC meeting is confirmed in the FDA regulatory history. The supplied FDA review summary does not provide the submitted questions or detailed meeting conclusions.TYPE_D · Meeting scope is captured in this strategy.
Type D study-analysis meetingFDA disagreed with a sponsor proposal in the ongoing VRDN-001-101 study; the specific proposal is redacted in the public review. FDA conveyed the appropriate imputation of missing data including MRI/CT data and requested a tipping-point sensitivity analysis. The sponsor abandoned the planned protocol amendment.TYPE_D · Meeting scope is captured in this strategy.
Type C CMC meetingA Type C CMC meeting is confirmed in the FDA regulatory history. The supplied FDA review summary does not provide the submitted questions or detailed meeting conclusions.TYPE_C · Meeting scope is captured in this strategy.
Type C BLA Format and Content meetingFDA stated the proposed initial BLA data package appeared acceptable for filing and review, agreed the ISE and ISS approach was acceptable if individual study results were also submitted, and agreed with a four-month safety update.TYPE_C · Meeting scope is captured in this strategy.
Type B pre-BLA meetingThe in-person pre-BLA meeting addressed adequacy of the two pivotal trials for BLA filing, draft labeling content, the pending Breakthrough Therapy Designation request, and Priority Review. The Administrative and Correspondence document confirms four sponsor questions.TYPE_B · 4 FDA questions
BLA mid-cycle meetingA BLA mid-cycle teleconference was held between FDA and the applicant. FDA stated that, based on the data available at that time, no safety issues required a REMS.Meeting scope is captured in this strategy.

Risks and fallback paths 5

Risks

Residual dose-optimization uncertaintyAt the End-of-Phase 2 meeting, FDA explicitly stated that it was premature to call 10 mg/kg the most safe and efficacious dose and encouraged further dose-ranging. The later clinical review accepted the registration regimen, but also noted that higher recurrence in chronic TED may warrant further dose-response exploration.Medium · Medium · Accepted
Durability declines after treatment, especially in chronic TEDFDA observed waning persistence after the five-infusion course. In chronic TED, the clinical review reported less persistence of effect than in active TED and a discrepancy between exophthalmometer and MRI/CT durability measurements; the review stated higher recurrence in chronic TED may warrant further dose-response exploration.Medium · Medium · Accepted
Black participants underrepresented; subgroup response uncertainFDA noted that Black participants were slightly underrepresented and the subgroup showed a lower clinical response across several efficacy analyses. FDA also noted the small subgroup size limited definitive conclusions and did not require a postmarketing study for this finding.Medium · Medium · Accepted
ADA/NAb assay drug-tolerance limitationFDA found inadequate drug tolerance in the antidrug-antibody and neutralizing-antibody assays, leaving the true incidence of low-to-mid titer ADAs and NAbs uncertain. FDA nevertheless concluded the available high-titer data did not show clinically significant PK, PD, safety or efficacy impact and did not require a postmarketing study.Medium · Low · Accepted
IGF-1R class safety risks require monitoringFDA identified infusion reactions, inflammatory bowel disease, hyperglycemia, and hearing impairment including hearing loss as important risks. FDA determined a REMS was not necessary and these risks could be managed through labeling and routine care.Medium · High · Accepted

Fallbacks

2021

2022

2023

2024

2025

2026

Jul

Aug

Sep

Oct

Nov

Dec

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

React Flow

›

Workstream / schedule object